ASLAN Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-99.13	-129.42	-66.84
Depreciation & Amortization	1.23	0.83	0.33
Loss (Gain) From Sale of Assets	-	-	0
Loss (Gain) From Sale of Investments	-	-	-0.06
Stock-Based Compensation	11.27	13.57	1.35
Other Operating Activities	60.86	91.62	42.99
Change in Accounts Payable	0.15	1.08	2.48
Change in Other Net Operating Assets	-0.9	-0.18	-0.3
Operating Cash Flow	-26.52	-22.51	-20.05
Capital Expenditures	-0.16	-0.56	-0.78
Investment in Securities	7.5	55.69	-30.64
Other Investing Activities	2.03	2.22	1.6
Investing Cash Flow	9.37	57.36	-29.82
Short-Term Debt Issued	14	284.93	-
Total Debt Issued	14	284.93	-
Short-Term Debt Repaid	-14	-284.93	-0.09
Long-Term Debt Repaid	-0.33	-0.3	-0.19
Total Debt Repaid	-14.33	-285.23	-0.28
Net Debt Issued (Repaid)	-0.33	-0.3	-0.28
Other Financing Activities	-0.13	-0.45	-14.06
Financing Cash Flow	-0.46	2.05	-14.34
Foreign Exchange Rate Adjustments	-0.19	-0.16	-0.48
Net Cash Flow	-17.79	36.74	-64.69
Free Cash Flow	-26.68	-23.06	-20.83
Free Cash Flow Margin	-266.77%	-	-
Free Cash Flow Per Share	-0.06	-0.05	-0.04
Cash Interest Paid	0.03	0.28	0.03
Cash Income Tax Paid	1.04	-0.08	0.22
Levered Free Cash Flow	-12.04	-122.15	-
Unlevered Free Cash Flow	-12.03	-121.98	-
Change in Working Capital	-0.76	0.89	2.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.